194 related articles for article (PubMed ID: 29872572)
1. Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas.
Qian Z; Li Y; Fan X; Zhang C; Wang Y; Jiang T; Liu X
Oncoimmunology; 2018; 7(6):e1434466. PubMed ID: 29872572
[No Abstract] [Full Text] [Related]
2. Long Non-coding RNA Expression Profiling Identifies a Four-Long Non-coding RNA Prognostic Signature for Isocitrate Dehydrogenase Mutant Glioma.
Chen Y; Guo Y; Chen H; Ma F
Front Neurol; 2020; 11():573264. PubMed ID: 33329315
[No Abstract] [Full Text] [Related]
3. Transcriptional Characteristics of
Chang YZ; Li GZ; Pang B; Zhang KN; Zhang XH; Wang YZ; Jiang ZL; Chai RC
Front Cell Dev Biol; 2020; 8():580464. PubMed ID: 33195221
[No Abstract] [Full Text] [Related]
4. Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses.
Liu YQ; Wu F; Li JJ; Li YF; Liu X; Wang Z; Chai RC
Front Oncol; 2019; 9():1433. PubMed ID: 31921684
[No Abstract] [Full Text] [Related]
5. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
6.
Liu X; Li Y; Li S; Fan X; Sun Z; Yang Z; Wang K; Zhang Z; Jiang T; Liu Y; Wang L; Wang Y
Aging (Albany NY); 2019 Jan; 11(2):673-696. PubMed ID: 30696801
[TBL] [Abstract][Full Text] [Related]
7. A novel tailored immune gene pairs signature for overall survival prediction in lower-grade gliomas.
Pan X; Wang Z; Liu F; Zou F; Xie Q; Guo Y; Shen L
Transl Oncol; 2021 Jul; 14(7):101109. PubMed ID: 33946034
[TBL] [Abstract][Full Text] [Related]
8. Identification of IDH-mutant gliomas by a prognostic signature according to gene expression profiling.
Wang Q; Wang Z; Li G; Zhang C; Bao Z; Wang Z; You G; Jiang T
Aging (Albany NY); 2018 Aug; 10(8):1977-1988. PubMed ID: 30115812
[TBL] [Abstract][Full Text] [Related]
9. An Immune-Related Prognostic Signature for Predicting Clinical Outcomes and Immune Landscape in IDH-Mutant Lower-Grade Gliomas.
Xiao G; Gao X; Li L; Liu C; Liu Z; Peng H; Xia X; Yi X; Zhou R
J Oncol; 2021; 2021():3766685. PubMed ID: 34961815
[TBL] [Abstract][Full Text] [Related]
10. An Autophagy-Related Gene Signature Associated With Clinical Prognosis and Immune Microenvironment in Gliomas.
Xu Y; Li R; Li X; Dong N; Wu D; Hou L; Yin K; Zhao C
Front Oncol; 2020; 10():571189. PubMed ID: 33194668
[TBL] [Abstract][Full Text] [Related]
11. Molecular and Clinicopathological Characterization of a Prognostic Immune Gene Signature Associated With MGMT Methylation in Glioblastoma.
Zhao L; Zhang J; Xuan S; Liu Z; Wang Y; Zhao P
Front Cell Dev Biol; 2021; 9():600506. PubMed ID: 33614641
[No Abstract] [Full Text] [Related]
12. Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.
Hu X; Martinez-Ledesma E; Zheng S; Kim H; Barthel F; Jiang T; Hess KR; Verhaak RGW
Neuro Oncol; 2017 Jun; 19(6):786-795. PubMed ID: 28340142
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of an immune-related gene signature for predicting the radiosensitivity of lower-grade gliomas.
Yan D; Zhao Q; Du Z; Li H; Geng R; Yang W; Zhang X; Cao J; Yi N; Zhou J; Tang Z
Sci Rep; 2022 Apr; 12(1):6698. PubMed ID: 35461367
[TBL] [Abstract][Full Text] [Related]
14. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
[TBL] [Abstract][Full Text] [Related]
15. Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma.
Wu F; Li GZ; Liu HJ; Zhao Z; Chai RC; Liu YQ; Jiang HY; Zhai Y; Feng YM; Li RP; Zhang W
J Pathol; 2020 Jul; 251(3):272-283. PubMed ID: 32418210
[TBL] [Abstract][Full Text] [Related]
16. A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma.
Patil V; Mahalingam K
Gene; 2018 Dec; 679():57-64. PubMed ID: 30077762
[TBL] [Abstract][Full Text] [Related]
17. A Novel Four-Gene Signature Associated With Immune Checkpoint for Predicting Prognosis in Lower-Grade Glioma.
Xiao Y; Cui G; Ren X; Hao J; Zhang Y; Yang X; Wang Z; Zhu X; Wang H; Hao C; Duan H
Front Oncol; 2020; 10():605737. PubMed ID: 33381460
[TBL] [Abstract][Full Text] [Related]
18. A Novel Signature Constructed by RNA-Binding Protein Coding Genes to Improve Overall Survival Prediction of Glioma Patients.
Tu Z; Shu L; Li J; Wu L; Tao C; Ye M; Zhu X; Huang K
Front Cell Dev Biol; 2020; 8():588368. PubMed ID: 33634092
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of a microRNA signature as a novel biomarker in patients with lower-grade gliomas.
Qian Z; Li Y; Fan X; Zhang C; Wang Y; Jiang T; Liu X
J Neurooncol; 2018 Mar; 137(1):127-137. PubMed ID: 29204839
[TBL] [Abstract][Full Text] [Related]
20. MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status.
Li G; Wang Z; Zhang C; Liu X; Yang F; Sun L; Liang J; Hu H; Liu Y; You G; Bao Z; Zhang W; Wang Z; Jiang T
Dis Markers; 2018; 2018():5975216. PubMed ID: 29887919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
